Mapping and Ablation of VT with Prior Myocardial Infarction

William G. Stevenson, MD Professor of Medicine Vanderbilt University Medical Center Nashville, Tennessee USA




VanderbiltHeart.com

William G Stevenson, MD

- Disclosures
 - Honoria
 - Abbott
 - Biotronik
 - Boston Scientific
 - Johnson and Johnson
 - Intellectual Property
 - Patent for irrigated needle ablation consigned to Brigham Hospital
 - Consulting
 - Novartis




VT post infarction




 Reentry involving regions of ventricular scar is the most common cause

Uncommon mechanisms

 Bundle branch reentry
 Focal Automaticity



Monomorphic VT can also be due to reentry circuits that are defined by functional conduction block



Stable reentry circuit isthmuses can be defined by defined by slow propagation transverse to fiber orientation and wavefront collision.

Slow conduction occurs at areas of high wavefront curvature at entrance and exit regions


High resolution mapping and entrainment of reentry in 6 – 8 wk old swine infarct model

Anter et al Circulation 2016


Multi-loop reentry:

- QRS morphology reflects the reentry circuit exit
 - Presystolic activation may indicate a channel, but can also originate from a bystander region

Channels can be defined by fixed or functional block



Catheter ablation of scar-related VT can be challenging




- If the substrate for one VT is present, multiple VTs are often inducible
- Infarcts associated with VT are often large
- Reentry substrate favors the subendocardium, but can be 3dimensional extending to intramural and subepicardial areas



Approaches to Catheter Ablation of Post MI VT


Target Isthmuses /channels of specific VTs


Endpoint Absence of inducible VT




Target all potential channels during sinus or paced rhythm

<u>Endpoint</u> - Absence of inducible VT and LP/LAVA - core isolation










Targeting the Specific VT Isthmus


- Incessant VT
- Known clinical VT
- Failed prior substrate ablation
- VT substrate in a high risk area
 - AV conduction at risk in basal septum
 - Epicardial
 - Adjacent to phrenic nerve
 - Adjacent to coronary artery




- left bundle branch block configuration in V1
 - LV septal exit
 - RV origin (<10%)
 - bundle branch reentry (5%)




- RV scar (5% of ischemic heart disease VT patients)
- Right bundle branch block configuration in V1
 - Left ventricular origin







ECG morphologies in mid precordial leads and VT exit / origin




Propagation during VT from multielectrode mapping

Voltage Map





RF termination of VT







If the clinically relevant VT is no longer inducible should more ablation be done?

Identifying potential channels during sinus or paced rhythm


• Markers of potential channels





LAVA = late potentials, or potentials fused with the the far-field ventricular signal during sinus rhythm, that become split potentials with pacing or VT

Jaïs P et al. Circulation 2012;125:2184-2196




Noninducibility and Late Potential Abolition: Combined End Point for Catheter Ablation of Postinfarction VT


Silberbauer et al Circulation Arrhyth EP 2014

159 post–MI patients undergoing first time ablation.

- 86% had inducible VT at baseline
- 65% had baseline LPs
 - LPs could not be abolished in 23% of pts with LPs.
- Follow-up:
 - 32% of pts had recurrent VT
 - abolition of LPs was associated with better outcome



VISTA: extensive substrate ablation vs targeting a clinical VT for hemodynamically tolerated post MI VT



Approach to the patient with multiple hemodynamically untolerated VTs

Approaches to Catheter Ablation of Post MI VT


Target Isthmuses /channels of specific VTs <u>Endpoint</u> Absence of inducible


VT


Requires hemodynamic support for extensive mapping of untolerated VTs

Target all potential channels during sinus or paced rhythm Endpoint - Absence of inducible VT and LP/LAVA


- core isolation








VT Substrates post MI



Extensive scar


- Large endocardial low bipolar voltage scar (< 1.5 mV)
- Typical of non-reperfused infarcts




Limited endocardial scar

- Small or no endocardial low bipolar voltage scar (< 1.5 mV)
- Typical of effectively reperfused infarcts


Evoked Delayed Potentials: a potential method for identifying VT substrate in borderzone areas RVA pacing 500 BCL; S2 = ERP + 50






Marta de Riva et al. JACEP 2018;4:316-327

Targeting the Hidden Substrate Unmasked by Right Ventricular Extrastimulation Improves Ventricular Tachycardia Ablation Outcome After Myocardial Infarction




Targeted Ablation of Ventricular Tachycardia Guided by Wavefront Discontinuities During Sinus Rhythm: A New Functional Substrate Mapping Strategy


Aziz, Tung et al Circulation 2019 online



VanderbiltHeart.com



Failure to achieve permanent ablation lesions: Recovery of inducible VT 3 days after ablation Noninvasive stim (NIPS) 3 days after ablation




Modified from Frankel et al JACC 2012

Adequate Lesion Creation

- Impedance fall > 10 15 Ohms
- Tissue whitening on intracardiac ultrasound
- Unexcitable to pacing at 10 ma 2ms

Recurrent VT after catheter ablation is associated with mortality/transplantation, (independent of EF and heart failure status).



The IVTCC Investigators: Freedom From Ventricular Tachycardia after Catheter Ablation Is Associated With Improved Survival in Patients With Structural Heart Disease: Heart Rhythm 2015 (in press) http://dx.doi.org/10.1016/j.hrthm.2015.05.036

BRIGHAM AND

WOMEN'S HOSPITAL

termountain

lealthcare

OSPEDALE SAN RAFFAELE





Cardiac Arrhythmia Cent

Complications of VT ablation in structural heart disease

Tung et al Heart Rhythm 2015

Patients	2061
Complications	6%
Death	0.1%
Vascular access	1.6%
Hemopericardium	1.7%
AV block	0.9%
Stroke/TIA	0.5%
coronary injury	0.2%

Antiarrhythmic Drug Escalation vs Ablation for recurrent VT in CAD

259 patients

- Prior MI, ICD, recurrent VT
- One of the Following VT Events despite drug therapy
 - \geq 3 episodes VT treated with ATP, with symptoms
 - \geq 1 appropriate ICD shock
 - \geq 3 VT episodes within 24 hours
 - Sustained VT below programmed ICD detection

Randomization stratified for center and amiodarone at study entry

Escalated Drug Therapy

- Sotalol \rightarrow Amiodarone load then 200 mg/d
- Amiodarone <300 \rightarrow Amio reload, then 300 mg/d
- Amio ≥300 mg/d \rightarrow Amio + Mexiletine 600 mg/d

<u>Ablation</u>

continue same drug


Sapp et al NEJM 2016

VANISH Trial Sapp et al NEJM 2015

Subgroup analysis

VT on amio – VT ablation superior to increasing amiodarone or adding mexiletine to amiodarone

VT on sotalol – ablation has similar efficacy to amiodarone



Primary Outcome: Death, VT Storm, Appropriate Shock

Treatment-Attributable Adverse Events

Event	Drug Group (n=127) No. (%)	Catheter Ablation (n=132) No. (%)	Р
Catheter Ablation Related			
Vascular injury		3 (2.3)	0.25
Major Bleeding	1 (0.8)	3 (2.3)	0.62
Cardiac Perforation	1 (0.8)	2 (1.5)	1.00
Endocarditis	1 (0.8)		0.49
Heart Block	1 (0.8)		0.49
Antiarrhythmic Drug Related			
Death			
Pulmonary toxicity	2 (1.6)		0.24
Liver toxicity/multiorgan failure	1 (0.8)		0.49
Pulmonary Infiltrate	2 (1.6)		0.24
Shortness of Breath	3 (2.4)	1 (0.8)	0.36
Heart Failure Admission	1 (0.8)	3 (2.3)	0.62
Hyperthyroidism	5 (3.9)	3 (2.3)	0.49
Hypothyroidism	5 (3.9)	2 (1.5)	0.27
Hepatic Dysfunction	6 (4.7)		0.013
Tremor/Ataxia	6 (4.7)		0.013
SFX Leading To Drug Therapy Change	6 (4.7)		0.013
Other adverse events no. (%)	6 (4.7)	4 (3.0)	0.53
TOTAL PATIENTS	39 (30.7)	20 (15.2)	0.0031
TOTAL EVENTS	51	22	0.0023


Catheter Ablation for VT due to prior Myocardial Infarction


- Important therapy for patients with recurrent VT
- Acceptable risk
- Strategies continue to evolve
- Inability to achieve durable lesions is a limitation

Thank you


VanderbiltHeart.com

Slow conduction: Zig - zag conduction caused by fibrotic separation of myocyte bundles De Bakker, et al. Circulation 1988; 77:589. Circulation 1993;88:915.






Entrainment with concealed fusion and PPI – TCL < 30 mms near but outside the isthmus exit of functionally defined reentry circuits



Anter et al Circulation 2016



Ablation at evoked delayed potential sites

Delayed hyperenhancement area from cardiac MR imaging

Bipolar voltage excluding "far-field" high voltage signals Many studies of substrate guided ablation incorporate mapping during VT

Elimination of Local Abnormal Ventricular Activities A New End Point for Substrate Modification in Patients With Scar-Related Ventricular Tachycardia

Jais et al Circulation 2012

"In patients in whom at least 1 VT was inducible and well tolerated (ie, 11 during the first intervention, 3 during subsequent interventions), <u>ablation was guided by</u> <u>conventional entrainment mapping criteria</u> to identify the critical isthmus."


Noninducibility and Late Potential Abolition: A Novel Combined Prognostic Procedural End Point for Catheter Ablation of Postinfarction Ventricular Tachycardia

Silberget et al Circ Arrhythm Electrophysiol 2014

"In patients with tolerated or hemodynamically supportable VT, VT was ablated using activation and entrainment mapping. After VT termination, ablation continued in SR aiming at the complete abolition of LPs (1A) when present or EPs when absent (1B)."

Targeted Ablation of Ventricular Tachycardia Guided by Wavefront Discontinuities During Sinus Rhythm: A New Functional Substrate Mapping Strategy

Aziz, Tung et al Circulation 2019 online



VanderbiltHeart.com